These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38309424)

  • 21. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern.
    Laufersweiler MC; Gadagbui B; Baskerville-Abraham IM; Maier A; Willis A; Scialli AR; Carr GJ; Felter SP; Blackburn K; Daston G
    Regul Toxicol Pharmacol; 2012 Feb; 62(1):160-82. PubMed ID: 22019814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protectiveness of NAM-based hazard assessment - which testing scope is required?
    Zobl W; Bitsch A; Blum J; Boei JJWA; Capinha L; Carta G; Castell J; Davoli E; Drake C; Fisher CP; Heldring MM; Islam B; Jennings P; Leist M; Pellegrino-Coppola D; Schimming JP; Snijders KE; Tolosa L; van de Water B; van Vugt-Lussenburg BMA; Walker P; Wehr MM; Wijaya LS; Escher SE
    ALTEX; 2024; 41(2):302-319. PubMed ID: 38048429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.
    Parfett CL; Desaulniers D
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using ToxCast to Explore Chemical Activities and Hazard Traits: A Case Study With Ortho-Phthalates.
    Pham N; Iyer S; Hackett E; Lock BH; Sandy M; Zeise L; Solomon G; Marty M
    Toxicol Sci; 2016 Jun; 151(2):286-301. PubMed ID: 26969370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of the limitations and uncertainties of in vivo developmental neurotoxicity testing and assessment to identify the potential for alternative approaches.
    Paparella M; Bennekou SH; Bal-Price A
    Reprod Toxicol; 2020 Sep; 96():327-336. PubMed ID: 32781019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using default methodologies to derive an acceptable daily exposure (ADE).
    Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of ecologically relevant in vitro bioassays to supplement current in vivo tests for whole effluent toxicity testing - Part 2: Non-apical endpoints.
    Finlayson KA; van de Merwe JP; Leusch FDL
    Sci Total Environ; 2022 Dec; 851(Pt 1):158094. PubMed ID: 35987232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A unified approach to risk assessment for cancer and noncancer endpoints based on benchmark doses and uncertainty/safety factors.
    Gaylor DW; Kodell RL; Chen JJ; Krewski D
    Regul Toxicol Pharmacol; 1999 Apr; 29(2 Pt 1):151-7. PubMed ID: 10341145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accelerating the Pace of Chemical Risk Assessment.
    Kavlock RJ; Bahadori T; Barton-Maclaren TS; Gwinn MR; Rasenberg M; Thomas RS
    Chem Res Toxicol; 2018 May; 31(5):287-290. PubMed ID: 29600706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
    Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term toxicogenomics as an alternative approach to chronic in vivo studies for derivation of points of departure: A case study in the rat with a triazole fungicide.
    LaRocca J; Costa E; Sriram S; Hannas BR; Johnson KJ
    Regul Toxicol Pharmacol; 2020 Jun; 113():104655. PubMed ID: 32268158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nano-risk Science: application of toxicogenomics in an adverse outcome pathway framework for risk assessment of multi-walled carbon nanotubes.
    Labib S; Williams A; Yauk CL; Nikota JK; Wallin H; Vogel U; Halappanavar S
    Part Fibre Toxicol; 2016 Mar; 13():15. PubMed ID: 26979667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tiered approach to systemic toxicity testing for agricultural chemical safety assessment.
    Doe JE; Boobis AR; Blacker A; Dellarco V; Doerrer NG; Franklin C; Goodman JI; Kronenberg JM; Lewis R; Mcconnell EE; Mercier T; Moretto A; Nolan C; Padilla S; Phang W; Solecki R; Tilbury L; van Ravenzwaay B; Wolf DC
    Crit Rev Toxicol; 2006 Jan; 36(1):37-68. PubMed ID: 16708694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methods for deriving pesticide aquatic life criteria.
    TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
    Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of ecologically relevant in vitro bioassays to supplement current in vivo tests for whole effluent toxicity testing - Part 1: Apical endpoints.
    Finlayson KA; Leusch FDL; van de Merwe JP
    Sci Total Environ; 2022 Dec; 851(Pt 1):157817. PubMed ID: 35970462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of data across toxicity endpoints for improved safety assessment of chemicals: the example of carcinogenicity assessment.
    Madia F; Pillo G; Worth A; Corvi R; Prieto P
    Arch Toxicol; 2021 Jun; 95(6):1971-1993. PubMed ID: 33830278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework.
    Thomas RS; Philbert MA; Auerbach SS; Wetmore BA; Devito MJ; Cote I; Rowlands JC; Whelan MP; Hays SM; Andersen ME; Meek ME; Reiter LW; Lambert JC; Clewell HJ; Stephens ML; Zhao QJ; Wesselkamper SC; Flowers L; Carney EW; Pastoor TP; Petersen DD; Yauk CL; Nong A
    Toxicol Sci; 2013 Nov; 136(1):4-18. PubMed ID: 23958734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a role for the no observed adverse effect level in safety pharmacology?
    Mow T; Andersen NK; Dragsted N; Lassen AB; Laursen M; Bass AS; Valentin JP; Markgraf C; Authier S; Baird TJ; Bhatt S; Traebert M; Leishman DJ; Jones D; Curtis MJ
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106917. PubMed ID: 32866658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A strategy for safety assessment of chemicals with data gaps for developmental and/or reproductive toxicity.
    Blackburn K; Daston G; Fisher J; Lester C; Naciff JM; Rufer ES; Stuard SB; Woeller K
    Regul Toxicol Pharmacol; 2015 Jul; 72(2):202-15. PubMed ID: 25910676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.